ReviewImmunological reviews2011
Challenges in the pursuit of immune tolerance.
Review in Immunological reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Immune Tolerance vs. Immune Resistance: The Interaction Between Host and Pathogens in Infectious Diseases.Frontiers in veterinary science · 2022Pooled it
- Induction of immune tolerance in NMOSD and MOGAD.Therapeutic advances in neurological disorders · 2025Review
- Hypoxia inducible factor-1α regulates microglial innate immune memory and the pathology of Parkinson's disease.Journal of neuroinflammation · 2024Article
- ERK Inhibition Promotes Engraftment of Allografts by Reprogramming T-Cell Metabolism.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Anti-Drug Antibodies: Emerging Approaches to Predict, Reduce or Reverse Biotherapeutic Immunogenicity.Antibodies (Basel, Switzerland) · 2018Review
- Vascular endothelial growth factor A is associated with the subsequent development of moderate or severe cardiac allograft vasculopathy in pediatric heart transplant recipients.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2017Article
- Tolerance in liver transplantation: Biomarkers and clinical relevance.World journal of gastroenterology · 2016Review
- A biodegradable killer microparticle to selectively deplete antigen-specific T cells in vitro and in vivo.Oncotarget · 2016Article
- Engineering nanoparticles to overcome barriers to immunotherapy.Bioengineering & translational medicine · 2016Review
- Tolerance induction in memory CD4 T cells requires two rounds of antigen-specific activation.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- Restoring the balance: immunotherapeutic combinations for autoimmune disease.Disease models & mechanisms · 2014Review
- Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.Anticancer research · 2012Review
- Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis.Frontiers in immunology · 2012Article
- Relevance of regulatory T cell promotion of donor-specific tolerance in solid organ transplantation.Frontiers in immunology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Strategies for inducing immune tolerance are fundamentally similar across a spectrum of immune-mediated disorders, including allergic disease, autoimmunity, and rejection of allografts. In each case, the objective of establishing an immunoregulatory balance is challenged by variable upswings in effector cell populations and proinflammatory mediators of immunity, requiring careful, and innovative therapeutic intervention to restore stability. The Immune Tolerance Network, an international consortium sponsored by the National Institutes of Health, seeks to advance both the scientific understanding and the clinical success of immune therapies for these disorders, through an innovative and collaborative effort involving clinical trials and mechanistic studies. Over the last decade, scientists have evaluated cell-based ablation and deviation strategies in trials using lymphocyte-specific targeting, induction of host-donor hematopoietic chimerism, induction of antigen-specific immune regulation, and a variety of antigen desensitization approaches. In this article, we review some of the highlights of this experience and discuss the potential for progress, utilizing new insights into regulatory mechanisms and biomarker signatures of tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.